



Published in final edited form as:

Eur Urol Oncol. 2020 December ; 3(6): 748–755. doi:10.1016/j.euo.2019.09.006.

Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer

Michael J. Zelefsky^{a,*}, Attapol Pinitpatcharalert^b, Marisa Kollmeier^a, Debra A. Goldman^c, Sean McBride^a, Daniel Gorovets^a, Zhigang Zhang^c, Melissa Varghese^a, Laura Happersett^d, Neelam Tyagi^d, Margie Hunt^d

^aDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA ^bDivision of Radiation Oncology, Thammasat University Hospital, Pathumthani, Thailand

^cDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer, New York, NY, USA ^dDepartment of Medical Physics, Memorial Sloan Kettering Cancer, New York, NY, USA

Abstract

Background: Studies using stereotactic body radiotherapy (SBRT) dose escalation in low- and intermediate-risk prostate cancer patients have indicated favorable outcomes.

Objective: To evaluate tolerance and tumor control outcomes in low- and intermediate-risk prostate cancer patients treated with high-dose SBRT following our phase 1 trial.

Design, setting, and participants: A total of 551 patients with low- or intermediate-risk prostate cancer were treated with SBRT.

Intervention: Treatment with 37.5–40 Gy SBRT in five fractions directed to the prostate and seminal vesicles.

Outcome measurements and statistical analysis: Outcome measurements included acute toxicities (<3 mo after radiotherapy [RT]) and late toxicities (>3 mo after RT) and tumor control evaluation (prostate-specific antigen [PSA] levels at 3–6-mo intervals and post-treatment prostate biopsy at 2 yr).

*Corresponding author. Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Tel. +1 212 639 6802; Fax: +1 212 639 8876. zelefskm@mskcc.org (M.J. Zelefsky).

Author contributions: Michael J. Zelefsky had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Zelefsky, Pinitpatcharalert, Kollmeier, Goldman, Gorovets.

Acquisition of data: Pinitpatcharalert, Varghese, Goldman, Gorovets.

Analysis and interpretation of data: Zelefsky, Kollmeier, Goldman, McBride, Gorovets, Zhang, Happersett, Hunt.

Drafting of the manuscript: Zelefsky, Goldman, Gorovets, Pinitpatcharalert.

Critical revision of the manuscript for important intellectual content: Zelefsky, Kollmeier, Goldman, McBride, Gorovets, Zhang, Varghese, Tyagi, Happersett, Hunt.

Statistical analysis: Goldman, Gorovets, Zhang.

Obtaining funding: Zelefsky.

Administrative, technical, or material support: Varghese.

Supervision: Zelefsky.

Other: None.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Results and limitations: Acute grade 2 gastrointestinal (GI) toxicities occurred in 1.8% of patients, and late grade 2 and 3 GI toxicities were observed in 3.4% and 0.4% of patients, respectively. Acute grade 2 genitourinary (GU) toxicities occurred in 10% of patients, and grade 3–5 acute GU toxicities were observed in 0.7% of patients. Late grade 2 and 3 GU toxicities were observed in 21.1% and 2.5% of patients, respectively. The use of a hydrogel rectal spacer was significantly associated with reduced late GI toxicity and lower odds of developing late GU toxicity. The median follow-up was 17 mo, and 53% of those with at least 2 yr of follow-up (103/193) had a biopsy performed. The 5-yr cumulative incidence of PSA failure was 2.1%, and the incidence of a positive 2-yr treatment biopsy was 12%. Limitations to this report include its retrospective nature and short follow-up time.

Conclusions: Favorable short-term outcomes were achieved with high-dose SBRT for low- and intermediate-risk disease. Severe late toxicities were observed and favorable tumor control was found.

Patient summary: We utilized stereotactic body radiotherapy, a form of external beam radiotherapy that delivers highly targeted high-dose treatment to the prostate, to treat over 500 localized prostate cancer patients in five sessions over 1.5 wk. Treatments were well tolerated without significant urinary or rectal side effects. Nearly 90% of those who underwent biopsies after treatment did not demonstrate residual active disease.

Keywords

Prostate cancer; Stereotactic body radiotherapy; Toxicity; Biopsy; Prostate-specific antigen; Rectal spacer

1. Introduction

Ultrahypofractionated stereotactic body radiotherapy (SBRT) regimens have increasingly been used to treat clinically localized prostate cancer [1–7]. We conducted a phase 1 dose escalation study in low- and intermediate-risk prostate cancer patients and demonstrated improved tumor control outcomes in patients who received 40 Gy prescription doses based on 2-yr post-treatment biopsies [8]. Favorable tolerance profiles may be attributed to the use of image guidance to track inter- and intrafraction motion and tight planning target volume (PTV) margins with magnetic resonance imaging (MRI)-computed tomography (CT) fusion for target delineation and normal tissue contouring.

Several single-institution reports have demonstrated favorable tolerance and 5-yr prostate-specific antigen (PSA) relapse-free survival outcomes for low- and intermediate-risk disease using dose levels in the range of 35–36.25 Gy. Follow-up at 5 yr showed that SBRT is well tolerated, with outcomes comparable with patients treated with conventionally fractionated intensity modulated radiation therapy (IMRT) [1–6]. Based on the available clinical evidence in the literature for low- and intermediate-risk patients, SBRT has recently become incorporated as part of treatment guidelines within the management of localized prostate cancer [9,10].

Pathologic assessments of local tumor control based on post-treatment biopsies have not been performed routinely when evaluating PSA relapse-free survival outcomes.

Additionally, there are limited data on toxicity outcomes when higher SBRT dose levels are used. This report summarizes our experience using high-dose SBRT for low- and intermediate-risk prostate cancer following our phase 1 trial. In this trial, we evaluated early tolerance outcomes of a large number of patients delivered with higher SBRT dose levels than what has been used traditionally.

2. Patients and methods

2.1. Treatment protocol

Between 2012 and 2017, 551 clinically localized prostate cancer patients were treated at a single institution with high-dose SBRT directed to the prostate and seminal vesicles with PTV prescription doses of 37.5 or 40 Gy delivered on alternating days at the Memorial Sloan Kettering Cancer Center. National Comprehensive Cancer Network risk stratification criteria were used to categorize patients.

Clinical target volume (CTV) represented prostate and bilateral seminal vesicles based on CT or MRI scans. The PTV applied a 5-mm margin around the anterior and lateral aspects of the CTV, with a 3-mm margin posteriorly and a 2-mm margin for its superior and inferior aspects. Organs at risk, including the rectum, bladder, femoral heads, large bowel, small bowel, bladder trigone, and urethra, were contoured.

The treatment planning approach for these patients has been described previously [8,11]. In brief, all patients underwent either electromagnetic transponder or fiducial marker placement under transrectal ultrasound guidance. These markers were used to confirm and monitor the prostate position before and during each SBRT treatment. Patients prior to 2015 received either electromagnetic transponders or fiducial placement. Subsequent to 2015, transponders were discontinued, and fiducial markers were placed in all patients. Beginning in November 2016, patients routinely underwent placement of hydrogel rectal spacer at the same time as fiducial marker placement (SpaceOAR; Augmenix Inc., Waltham, MA, USA).

Patients were simulated with an empty rectum and full bladder 1 wk after placement. While details of these guidelines varied slightly over the study, the main components remained the same. Patients were instructed to take an enema the day prior to and the day of simulation, and on the day of treatment. During simulation, patients underwent Foley catheter insertion for urethral visualization. Patients were immobilized in the supine position with a custom thermoplastic mold extending from the abdomen to mid-thigh and ankle support (Aquaplast). Starting in early 2015, CT simulation was performed with a 2-mm slice thickness extending from LI to well below the ischial tuberosities. Starting in early 2015, CT simulation was followed by magnetic resonance (MR) simulation on a 3T scanner in the treatment position, incorporating patient immobilization via the use of an indexed, flat tabletop. Since June 2016, we have routinely used MR-only simulation and planning for prostate SBRT [12,13]. MR-based contouring was performed in 346 patients (63%) using T2-weighted MRI.

Dose-volume constraints for target and normal tissue structures used in treatment planning have been described previously [8]. The standard PTV D95 was 90–100% of the prescription

dose; the maximum PTV dose did not exceed 112% of the prescription dose, and the mean dose to the PTV was 99–104% of the prescription, while meeting normal tissue constraints. In general, patients were treated with three or four volumetric arcs (volumetric modulated arc therapy [VMAT]).

SBRT was initiated within 2 wk following simulation. A treatment regimen, including a full bladder without a catheter and an empty rectum, was carried out before each treatment day. Matching of fiducial markers was checked using a kilovoltage on-board imaging for interfraction target position correction. A pretreatment cone beam CT (CBCT) scan was obtained prior to each fraction. A rectal catheter was used to remove gas if the cone beam imaging detected excessive air. CBCT images were shifted until completely overlaid with the simulated target; another CBCT scan was acquired for verification. Motion during treatment delivery was assessed by tracking electromagnetic transponders, or, for patients with implanted fiducials, kilovoltage imaging between VMAT arcs, once every three IMRT fields, or triggered kilovoltage on-board imaging every 20° was used for assessment. Beginning in 2016, a custom-developed approach combining triggered kilovoltage imaging with megavoltage short-arc digital tomography was used [14].

In general, patients were followed at 3 mo following radiotherapy (RT), and subsequently for every 3–6 mo for the first 5 yr and annually thereafter. Patients were evaluated for rectal and urinary toxicities according to the Common Terminology Criteria for Adverse Events, version 3.0, grading system. Acute toxicities were defined as those that occurred within 3 mo following RT, and late toxicities were those observed after 3 mo [15]. PSA levels were obtained at 3 mo following RT and 6 mo thereafter. Patients who reached 2 yr of follow-up after treatment were encouraged to undergo post-treatment prostate biopsy. The median follow-up was 17 mo, and 53% of those with at least 2 yr of follow-up (103/193) had a biopsy performed. Patients who were over the age of 80 yr and those on anticoagulants were not evaluated with post-treatment biopsies. Biochemical failure was assessed using the Phoenix definition (PSA nadir plus 2 ng/ml).

2.2. Statistical analysis

Toxicity rates were estimated by grade. For grade 2 toxicity estimates, binomial exact confidence intervals (CIs) were provided. The duration of each late toxicity event was calculated from the time of toxicity until resolution. Patients with unresolved toxicities at the end of follow-up were censored. Kaplan-Meier methods were used to estimate the median duration of late grade 2 toxicities with 95% CIs. We estimated the duration of toxicities only where at least 10 patients were observed to experience an event. Associations between baseline characteristics, including age, prostate volume, International Prostate Symptom Score (IPSS) score (for genitourinary [GU]), RT dose, and use of rectal spacer with any gastrointestinal (GI) and any GU grade 2–3 events, were assessed with univariable logistic regression. If more than one factor was significant on univariable analyses at $p < 0.05$, multivariable analyses were built. IPSS scores were dichotomized into <15 and ≥ 15 . The IPSS constraint was recommended only for our prior phase 1 study, but subsequently treated patients were deemed eligible for SBRT even at higher IPSS scores [8].

PSA failure was estimated from the start of RT until biochemical relapse. Death without recurrence was treated as a competing risk; patients without biochemical recurrence who survived were censored. Cumulative incidence indicated PSA failure. No estimates were provided since no distant metastases occurred at the end of follow-up. The rate of positive biopsies after RT was provided. Associations between positive biopsy and baseline characteristics were assessed with univariable logistic regression.

Two-sided *p* values of <0.05 were considered statistically significant. All analyses were performed with SAS 9.4 (The SAS Institute, Cary, NC, USA).

3. Results

3.1. Patient characteristics

The median age of the 551 patients was 70 yr (range: 47–89 yr; Table 1). The median initial PSA was 6.4 ng/ml (range: 0.3–19.6 ng/ml), and the majority of patients were Gleason group 1 (3 + 4; 63.3%; 349/551) and clinical stage T1c (72.8%; 401/551). Of those patients with available prostate volume data (*n* = 529), the median was 38 cc (interquartile range [IQR]: 28–53). Fifty-three patients (9.6%) were at low risk, 226 (41%) at favorable intermediate risk, and 272 (49.4%) at unfavorable intermediate risk. The percentage of positive biopsy cores per patient was as follows: 20%: 126 (23%); >20–50%: 271 (49%); and >50%: 154 (28%). There was a small percentage of low-risk patients (10%), and patients with intermediate-risk disease had three or more positive biopsy cores routinely; most of our patients had 50% or higher core involvement. All 551 patients had percent positive biopsy core information available; the median percent was 33.3% with an IQR of 21.4–50.0. Extraprostatic extension was present in 4% (22/551; a T3 category was based on MRI), and seminal vesical invasion was noted in 0.5% of patients (three/551). The IPSS median score, available in 547 patients, was 6 (IQR: 3–11).

Most patients received 40.0 Gy (85.5%; 471/551) in 8 Gy fractions. Approximately half of the patients received a rectal spacer (48.8%; 269/551) when it became available after the approval of the Food and Drug Administration in 2016. Androgen deprivation therapy (ADT) was given to 151 patients (27.4%); of those with available data (*n* = 133), the median duration of hormone therapy was 5.9 mo (IQR: 4.1–6.2 mo; Table 1).

3.2. Grade 2 and 3 toxicity estimates

Acute grade 2 GI toxicities occurred in 1.8% (95% CI: 0.9–3.3%) of patients (*n* = 10); no grade 3 acute GI toxicities were noted. Late grade 2 and 3 GI toxicities were observed in 19 (3.4%) and two (0.4%) patients, respectively, for a total grade 2+ rate of 3.8% (95% CI: 2.4–5.8%). Acute grade 2 GU toxicities occurred in 55 (10%) patients, and grade 3 acute GU toxicities were observed in four patients (0.7%), for a grade 2+ rate of 10.7% (95% CI: 8.3–13.6%). Late grade 2 and 3 GU toxicities were observed in 116 (21.1%) and 14 (2.5%) patients, respectively, for a grade 2+ rate of 23.6% (95% CI: 20.1–27.4%; Table 2).

We used time-to-event methods for late toxicity duration estimates in those with at least 10 events since some toxicity events remained unresolved. The median estimate for late grade 2 GI hemorrhage was 3.4 mo (95% CI: 0.2–8.6). The median estimates for late grade 2 GU

toxicity were 9.7 mo (95% CI: 6.4–15.2) for retention, 9.1 mo (95% CI: 6.5–12.0) for frequency/urgency, 1.0 mo (95% CI: 0.1–1.9) for GU hemorrhage, and 9.1 mo (95% CI: 5.0–12.3) for incontinence (Table 3).

3.3. Associations between GI/GU grade 2–3 toxicities and baseline characteristics

Older patients had lower odds of experiencing a grade 2+ acute GI toxicity (hazard ratio [HR]: 0.91; 95% CI: 0.83–0.99; $p = 0.028$). No significant association was found between prostate volume ($p = 0.31$) or hormone therapy ($p = 0.85$) with acute GI toxicity. As only 10 acute GI toxicities occurred, no multivariable models were built (Table 4).

Patients who underwent rectal spacer placement experienced significantly fewer late grade 2+ GI toxicity events compared with those who did not undergo placement (odds ratio [OR]: 0.24; 95% CI: 0.08–0.71; $p = 0.010$). The incidence of grade 2+ late rectal toxicity in the hydrogel and nonhydrogel spacer cohorts was 1% and 6%, respectively ($p = 0.01$). No other variables were significantly associated with late GI toxicity ($p = 0.18–0.55$); thus, no multivariable models were built (Table 4).

No baseline factors were associated with acute grade 2+ GU toxicities ($p = 0.19–0.42$); however, patients who underwent rectal spacer placement had lower odds of developing late GU toxicity (HR: 0.37; 95% CI: 0.25–0.57; $p < 0.001$). The incidence of grade 2+ late GU toxicity in the hydrogel and nonhydrogel spacer cohorts was 15% and 32%, respectively ($p < 0.001$). Additionally, patients with higher IPSS scores had higher odds of late GU toxicity (OR: 1.09; 95% CI: 1.05–1.13; $p < 0.001$). The association when IPSS score was dichotomized into ≥ 15 versus < 15 approached but did not reach significance (OR: 1.76; 95% CI: 0.99–3.15; $p = 0.055$); no other factors were significantly associated with late GU toxicity ($p = 0.24–0.79$; Table 4). In a multivariable model with IPSS score and rectal spacer, both factors remained significantly associated with late grade 2+ GU toxicities; patients with higher IPSS scores had a higher odds of toxicity (OR: 1.08; 95% CI: 1.05–1.13; $p < 0.001$) and patients with rectal spacer placement had a lower odds of toxicity (OR: 0.37; 95% CI: 0.25–0.57; $p < 0.001$).

3.4. Clinical outcomes

The median follow-up in survivors ($n = 543$) was 17.0 mo (IQR: 7–29 mo). In survivors, 17% of patients ($n = 92$) had at least 3 yr of follow-up. The 5-yr cumulative incidence of PSA failure was 2.1% (95% CI: 0.6–5.3%). No patients experienced distant metastases events at follow-up.

Of the 119 patients with a follow-up biopsy, 11.8% (95% CI: 6.6–19.0%) had a positive biopsy, 56.3% (95% CI: 46.9–65.4%) a negative biopsy, and 31.9% (95% CI: 23.7–41.1%) a treatment effect biopsy. The incidence of a positive biopsy among patients who received 37.5 Gy was 17.9% (95% CI: 6.1–36.9%), and this incidence was 9.9% (95% CI: 4.6–17.9%) for patients who were treated with 40 Gy. The median time between RT and post-RT biopsy was 25.2 mo (IQR: 24.3–28.1); none of the baseline factors were significantly associated with post-RT biopsy results ($p = 0.29–0.82$; Table 5).

4. Discussion

In this trial, we evaluated early tolerance outcomes of a large number of patients delivered with higher SBRT dose levels than what has been used traditionally. The patient population we treated consisted predominantly of intermediate-risk disease (>90%), in which the overwhelming majority had three more core positive cores, and where almost 50% of patient had 50% positive cores often with a visible lesion noted on baseline diagnostic MRI. We found minimal incidence of acute and late grade 3 urinary or rectal toxicities in patients who received high-dose SBRT. The most common grade 2+ late toxicities were urinary-related manifestations (chronic urethritis with associated frequency or urgency and hematuria). Late rectal toxicity manifesting as grade 2 rectal bleeding was noted in 2.5% of cases, consistent with other reports using lower SBRT doses (35–36.25 Gy in five fractions). Our findings are consistent with toxicity outcomes from a multicenter study of low- and intermediate-risk patients treated with 40 Gy in five fractions [6]. The favorable toxicity profile that we report is at least comparable with what we have previously observed using high-dose IMRT and similar as well to what was reported in a recently completed phase 3 trial that compared an SBRT regimen with 78 Gy of conventionally fractionated IMRT [16,17].

The low-toxicity outcomes in this study may be attributed to using dose-volume constraints for critical normal structures and application of tight margins around the CTV. We used restrictive selection criteria, including selecting patients with prostate sizes <80 cc and IPSS scores <15 (late urinary toxicity was not significantly higher in patients with higher IPSS scores (>15)).

At our institution, we routinely monitor intrafraction motion and adjust target position. We demonstrated reduced urinary toxicity rates in patients who underwent corrections of interfraction motion via delivery of conventionally fractionated external beam radiation therapy [18]. Since 2016, we have integrated MRI-based contouring and treatment planning without using CT-MRI fusion to delineate the apex and prostatic base [12,13]. Since 2016, all eligible SBRT patients have undergone hydrogel spacer placement to reduce exposure. Here, we observed lower rates of late GI- and GU-related toxicities associated with rectal spacer placement, consistent with reports that used conventionally fractionated external beam RT. Our results are consistent with the outcomes of a phase 3 trial reported by Hamstra et al [19] who found significantly improved urinary and rectal quality of life outcomes in a hydrogel spacer cohort compared with a control group. However, it should be noted that our study was not powered or designed to make definitive claims about rectal spacer benefit. In addition, as spacer placement was ubiquitous after 2016 unless contraindicated, we cannot separate out whether the association that we found was confounded by an underlying effect of time period.

Potential benefits of dose intensification must be balanced with risks of late normal tissue toxicity. Prospective clinical trials have demonstrated that higher doses significantly improve disease-free survival outcomes in intermediate-risk patients [20–26]. Phase 3 studies of dose intensification with three-dimensional conformal radiation therapy/IMRT or combined brachytherapy and treatment regimens have found a concomitant increase in the risk of late normal tissue toxicity [27]. The innovations used may synergistically result in the favorable

toxicity profile that we observed. The relatively low toxicity observed in this cohort could possibly be related to several specific technical factors, which include careful delineation of the target with adherence to dose-volume constraints, use of tight margins around the target volume, rectal protection, and correction for intrafraction motion.

A phase 1 dose escalation study reported improved outcomes using higher radiation dose levels [8]. Although escalated doses beyond 40 Gy (45–50 Gy) have been associated with increased rectal toxicity, a recent study suggested significant reduction of toxicity in patients treated with 45 Gy in five fractions using a hydrogel spacer [28]. Current trials comparing moderate hypofractionation regimens with ultrahypofractionation have used SBRT dose levels of 35–36.25 Gy in five fractions; however, these doses may not be sufficient to eradicate intermediate-risk disease, as optimal SBRT dosing must be confirmed through trials.

Limitations to this report include its retrospective nature and, subsequent to follow-up, the number of patients who received post-treatment biopsy. Additionally, no definitive conclusions can be made on cancer control with short-term follow-up. This study was underpowered to examine post-treatment outcomes related to the use of ADT in conjunction with SBRT. However, this study demonstrates the feasibility and early tolerance to high-dose SBRT using strict planning guidelines. We also confirmed low positive post-treatment biopsy outcomes in patients treated with 40 Gy SBRT; among patients with positive biopsies, the majority had unfavorable intermediate-risk disease, indicating that higher doses may be required for advanced disease risk [8]. The overwhelming majority of the patients in this study had intermediate-risk disease having, in most cases, at least several positive cores, generally with a visible lesion on MRI; in addition, almost half of the patients had 50% or more positive biopsy core involvement. Therefore, this population was not favorable, although not high risk.

Several randomized trials are underway comparing moderate hypofractionated regimens or conventionally fractions regimens with SBRT. Widmark et al [17] reported early toxicity results from the HYPO-RT trial comparing a conventionally fractionated regimen with SBRT in which a 6.1 Gy dose was delivered in seven weekly fractions. Nevertheless, there is no evidence to date that the ultrahypofractionated regimen is associated with higher toxicity. Despite potential limitations, our findings may validate that an ultrashort course of treatment using SBRT does not compromise tumor control and toxicity outcomes.

5. Conclusions

Favorable tumor control rates were achieved in patients with low- and intermediate-risk prostate cancer. Urinary and rectal toxicity rates were low and comparable with conventional IMRT. The 2-yr post-treatment positive biopsy rates noted among patients treated with this high-dose SBRT regimen was 17.9% for those treated with 37.5 Gy and 9.9% for those treated with 40 Gy. Given the short-term follow-up in this patient population, no definitive conclusions can be made about long-term tumor control outcomes.

Acknowledgments:

We acknowledge the excellent editorial assistance of Loren Devito, PhD.

Financial disclosures: Michael J. Zelevsky certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Michael J. Zelevsky is a consultant for Boston Scientific.

Funding/Support and role of the sponsor: This research was partially supported by the NIH/NCI Cancer Center Support Grant/Core Grant (P30 CA008748).

References

- [1]. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. *Radiother Oncol* 2013; 109:217–21. [PubMed: 24060175]
- [2]. King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2012;82:877–82. [PubMed: 21300474]
- [3]. Katz A Stereotactic body radiotherapy for low-risk prostate cancer: a 10-year analysis. *Cureus* 2017;9:e1668. [PubMed: 29152425]
- [4]. Henderson DR, Tree AC, van As NJ. Stereotactic body radiotherapy for prostate cancer. *Clin Oncol* 2015;27:270–9.
- [5]. Mantz C A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. *Front Oncol* 2014;4:279. [PubMed: 25452933]
- [6]. Meier RM, Bloch DA, Cotrutz C, et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. *Int J Radiat Oncol Biol Phys* 2018;102:296–303. [PubMed: 30191864]
- [7]. Gonzalez-Motta A, Roach M 3rd. Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: where are we now? *Pract Radiat Oncol* 2018;8:185–202. [PubMed: 29339046]
- [8]. Zelevsky MJ, Kollmeier M, McBride S, et al. 5-Year outcomes of a Phase I dose escalation study using stereotactic body radiosurgery for patients with low and intermediate risk prostate cancer. *Int J Radiat Oncol Biol Physics* 2019;104:42–9.
- [9]. Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. *Int J Radiat Oncol Biol Phys* 2019;104:778–89. [PubMed: 30959121]
- [10]. Morgan C, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline. *J Clin Oncol* 2018;36:3411–30.
- [11]. Pinitpatcharalert A, Happersett L, Kollmeier M, et al. Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer. *Adv Rad Oncol* 2019;4:337–44.
- [12]. Tyagi N, Fontenla S, Zelevsky M, et al. Clinical workflow for MR-only simulation and planning in prostate. *Radiat Oncol* 2017;12:119. [PubMed: 28716090]
- [13]. Tyagi N, Fontenla S, Zhang J, et al. Dosimetric and workflow evaluation of first commercial synthetic CT software for clinical use in pelvis. *Phys Med Biol* 2017;62:2961–75. [PubMed: 27983520]
- [14]. Hunt M, Sonnick M, Pham H, et al. Simultaneous MV-kV imaging for intrafractional motion management during volumetric-modulated arc therapy delivery. *J Appl Clin Med Phys* 2016;17:473–86. [PubMed: 27074467]

- [15]. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *Int J Radiat Oncol Biol Phys* 1995;31:1341–6. [PubMed: 7713792]
- [16]. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelevsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2013;85:686–92. [PubMed: 22795805]
- [17]. Widmark A, Gunnlaugsson A, Beckman L, et al. Ultrahypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, noninferiority, phase 3 trial. *Lancet* 2019;394:385–95. [PubMed: 31227373]
- [18]. Zelevsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2012;84:125–9. [PubMed: 22330997]
- [19]. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. *Int J Radiat Oncol Biol Phys* 2017;97:976–85. [PubMed: 28209443]
- [20]. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high - dose - rate brachytherapy boost for localised prostate cancer. *Radiother Oncol* 2012;103:217–22. [PubMed: 22341794]
- [21]. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. *J Clin Oncol* 2005;23:1192–9. [PubMed: 15718316]
- [22]. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. *Lancet Oncol* 2007;8:475–87. [PubMed: 17482880]
- [23]. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95 - 09. *J Clin Oncol* 2010;28:1106–11. [PubMed: 20124169]
- [24]. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. *J Clin Oncol* 2006;24:1990–6. [PubMed: 16648499]
- [25]. Beckendorf V, Guerif S, Le Prise E et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. *Int J Radiat Oncol Biol Phys* 2004;60:1056–65. [PubMed: 15519775]
- [26]. Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2017;98:275–85. [PubMed: 28262473]
- [27]. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2017;98:286–95. [PubMed: 28433432]
- [28]. Folkert MR, Zelevsky MJ, Hannan R, et al. Multi-institutional phase 2 trial of high-dose stereotactic body radiation therapy with temporary hydrogel spacer for low- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol* 2017;99:1319–20.

Table 1 –Patient and clinical characteristics^a

		<i>N</i> (%)
Patients, <i>n</i>		551
Age at SBRT (yr)	Median (IQR; <i>N</i> = 551)	70 (65–74)
Clinical T stage	T1a	3 (0.5)
	T1c	401 (72.8)
	T2a	104 (18.9)
	T2b	34 (6.2)
	T2c	9(1.6)
Initial PSA (ng/ml)	Median (range; <i>N</i> = 551)	6.4 (0.3–19.6)
Gleason score	Group 1 (3 + 3)	67 (12.2)
	Group 2 (3 + 4)	349 (63.3)
	Group 3 (4 + 3)	135 (24.5)
Prostate volume	Median (IQR; <i>N</i> = 529)	38.0 (28.0–53.0)
Prognostic risk group	Low	53 (9.6)
	Favorable-intermediate	226 (41)
	Unfavorable-intermediate	272 (49.4)
ECE	Unknown	18 (3.3)
	Negative	363 (65.9)
	Possible	71 (12.9)
	Suspicious	77 (14)
	Positive	22 (4)
SVI	Unknown	18 (3.3)
	Negative	527 (95.6)
	Possible	1 (0.2)
	Suspicious	2 (0.4)
	Positive	3 (0.5)
Lymphadenopathy	Unknown	18 (3.3)
	Negative	533 (96.7)
% Positive cores	Median (IQR; <i>N</i> = 551)	0.3 (0.2–0.5)
IIEF baseline score	Median (IQR; <i>N</i> = 530)	9.0 (2.0–25.0)
IPSS baseline score	Median (IQR; <i>N</i> = 547)	6.0 (3.0–11.0)

ECE = extracapsular extension; IIEF = International Index of Erectile Function; IPSS = International Prostate Symptom Score; IQR = interquartile range; PSA = prostate-specific antigen; SBRT = stereotactic body radiotherapy; SVI = seminal vesicle invasion.

^aNumbers in parentheses represent frequency with percent of total unless otherwise stated.

Table 2 –

Grade 2 toxicity estimates^a

	Timing					
	Acute			Late		
Grade 2 toxicity	Rate (%)	95% CI (%)	Fraction	Rate (%)	95% CI (%)	Fraction
<i>Any GI toxicity</i>	1.8	0.9–3.3	10/551	3.6	2.2–5.6	20/551
Diarrhea	0.2	0–1.0	1/551	0.5	0.1–1.6	3/551
GI hemorrhage	0.2	0–1.0	1/551	2.2	1.1–3.8	12/551
Hemorrhoids	0.7	0.2–1.8	4/551	1.5	0.6–2.8	8/551
Proctitis	0.9	0.3–2.1	5/551	0.5	0.1–1.6	3/551
<i>Any GU toxicity</i>	10.2	7.8–13.0	56/551	22.7	19.3–26.4	125/551
Cystitis	0.9	0.3–2.1	5/551	0.4	0–1.3	2/551
Frequency/urgency	8.7	6.5–11.4	48/551	14.3	11.5–17.5	79/551
Incontinence	0.9	0.3–2.1	5/551	2.9	1.7–4.7	16/551
<i>GU hemorrhage</i>	0.0	0–0.7	0/551	2.0	1–3.5	11/551
Retention	2.2	1.1–3.8	12/551	8.7	6.5–11.4	48/551
Urinary stricture				0.5	0.1–1.6	3/551

CI = confidence interval; GI = gastrointestinal; GU = genitourinary.

^a Acute urinary stricture was not measured. Fifty-six patients had any grade 2 GU acute toxicity, but one of these patients also had Grade 3 toxicity. Therefore, 55 patients had a maximum grade of 2. Twenty patients had any grade 2 GI late toxicity, but one of these patients also had grade 3 toxicity. Therefore, 19 patients had a maximum grade of 2.

Table 3 –

Toxicity proportions by maximum grade^a

	Timing, n (%)						
	Acute			Late			
	Grade 1	Grade 2	Grades 3-5	Grade 1	Grade 2	Grades 3-5	
Any GI toxicity	55 (10)	10 (1.8)	0 (0)	100 (18.1)	19 (3.4)	2 (0.4)	
Diarrhea	20 (3.6)	1 (0.2)		28 (5.1)	3 (0.5)		
GI hemorrhage	17 (3.1)	1 (0.2)	0 (0)	34 (6.2)	12 (2.2)	2 (0.4)	
Hemorrhoids	31 (5.6)	4 (0.7)		72 (13.1)	8 (1.5)		
Proctitis	6 (1.1)	5 (0.9)		3 (0.5)	3 (0.5)		
Any GU toxicity	173 (31.4)	55 (10)	4 (0.7)	196 (35.6)	116 (21.1)	14 (2.5)	
Cystitis	21 (3.8)	5 (0.9)		2 (0.4)	2 (0.4)		
Frequency/urgency	160 (29)	48 (8.7)	2 (0.4)	211 (38.3)	79 (14.3)	8 (1.5)	
GU hemorrhage	9 (1.6)	0 (0)	0 (0)	28 (5.1)	11 (2)	2 (0.4)	
Incontinence	29 (5.3)	5 (0.9)	0 (0)	61 (11.1)	16 (2.9)	3 (0.5)	
Retention	42 (7.6)	12 (2.2)	2 (0.4)	98 (17.8)	48 (8.7)	4 (0.7)	
Urinary stricture					3 (0.5)		

GI = gastrointestinal; GU = genitourinary.

^aNumbers in parentheses represent frequency with percent of total. Acute urinary stricture was not measured. Fifty-six patients had any grade 2 GU acute toxicity, but one of these patients also had grade 3 toxicity. Therefore, 55 patients had a maximum grade of 2. Twenty patients had any grade 2 GI late toxicity, but one of these patients also had grade 3 toxicity. Therefore, 19 patients had a maximum grade of 2.

Table 4 –

Multivariable associations between baseline factors and outcomes (grades 2–3)^{a,b}

		Acute				Late				
		N (%)	OR	95% CI	p value	N (%)	OR	95% CI	p value	
Any GI toxicity	Prostate volume		0.98	0.94–1.02	0.31		0.99	0.97–1.02	0.55	
	Age at SBRT (yr)		0.91	0.83–0.99	0.028		0.98	0.92–1.04	0.45	
	Hormone therapy	Yes	3 (2)	1.14	0.29–4.46	0.85	3 (2)	0.43	0.12–1.48	0.18
		No	7 (2)	REF			18 (5)	REF		
Any GU toxicity	Rectal spacer	Yes	2 (1)	0.26	0.05–1.22	0.09	4 (1)	0.24	0.08–0.71	0.010
		No	8 (3)	REF			17 (6)	REF		
	Prostate volume		1.01	0.99–1.02	0.42		1.01	1.00–1.01	0.24	
	Age at SBRT (yr)		1.02	0.98–1.06	0.35		1.00	0.98–1.03	0.79	
Any GU toxicity	Hormone therapy	Yes	20 (13)	1.41	0.80–2.51	0.24	34 (23)	0.92	0.59–1.44	0.71
		No	39 (10)	REF			96 (24)	REF		
	Rectal spacer	Yes	24 (9)	0.69	0.40–1.20	0.19	40 (15)	0.37	0.25–0.57	<0.001
		No	35 (12)	REF			90 (32)	REF		
IPSS baseline score	IPSS baseline score		1.04	0.99–1.09	0.09		1.09	1.05–1.13	<0.001	
	IPSS baseline score (grouped)	15	1.13	0.49–2.61	0.78	20 (34)	1.76	0.99–3.15	0.055	
		<15	52 (11)	REF			110 (23)	REF		

CI = confidence interval; GI = gastrointestinal; GU = genitourinary; IPSS = International Prostate Symptom Score; N = total number for level; OR = odds ratio; REF = reference; SBRT = stereotactic body radiotherapy.

^aModels assess probability of experiencing toxicity; OR >1 indicates higher odds of toxicity; OR <1 indicates lower odds of toxicity.

^bFor continuous factors, odds ratio corresponds to a one-unit increase.

Table 5 –Univariable associations between baseline factors and post-RT biopsy outcome ($N = 119$)^{a,b}

		<i>N</i> (# <i>O</i>)	OR	95% CI		<i>p</i> value
Prostate volume		117 (14)	1.00	0.98–	1.03	0.82
Hormone therapy	Yes	18 (1)	0.40	0.05–	3.25	0.39
	No	101 (13)	REF			
MSK risk	Unfavorable-intermediate	57 (9)	3.19	0.38–	27.05	0.29
	Favorable-intermediate	44 (4)	1.70	0.18–	16.34	0.65
	Low	18 (1)	REF			

CI = confidence interval; MSK = Memorial Sloan Kettering Cancer Center; *N* = total number for level; #*O* = number of positive biopsies for level; OR = odds ratio; REF = reference; RT = radiotherapy.

^aModels assess probability of experiencing toxicity; OR >1 indicates higher odds of toxicity; OR <1 indicates lower odds of toxicity.

^bFor continuous factors, odds ratio corresponds to a one-unit increase.